Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Not Confirmed
Not Confirmed
12-14 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Not Confirmed
12-14 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
22 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/22/2967317/0/en/Ocuphire-Pharma-Announces-Acquisition-of-Opus-Genetics.html
20 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/20/2932762/0/en/Opus-Genetics-Receives-Rare-Pediatric-Disease-Designation-from-the-U-S-FDA-for-Ocular-Gene-Therapy-OPGx-LCA5-to-Treat-Rare-Inherited-Retinal-Disease-LCA5.html
13 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/13/2898223/0/en/Opus-Genetics-Announces-1-7-Million-in-Project-based-Funding-from-the-Foundation-Fighting-Blindness-to-Support-Two-Preclinical-Programs.html
26 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/03/26/2852307/0/en/Opus-Genetics-Announces-Completion-of-Dosing-in-First-Cohort-of-Phase-1-2-Trial-of-Gene-Therapy-OPGx-LCA5-in-Patients-with-Rare-Inherited-Retinal-Disease-LCA5.html
03 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/03/2773418/0/en/New-Preliminary-Clinical-Data-on-Potential-of-Opus-AAV-based-Gene-Therapy-for-Rare-Inherited-Retinal-Disease-to-be-Presented-at-the-American-Academy-of-Ophthalmology-Annual-Confere.html
07 Sep 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/09/07/2739303/0/en/Opus-Genetics-Announces-First-Patient-Dosed-in-Phase-1-2-Trial-of-Gene-Therapy-OPGx-LCA5-in-Patients-with-Rare-Inherited-Retinal-Disease-LCA5.html
Details:
The acquisition creates a leading, clinical-stage company focused on developing gene therapies, including APX3330, an oral small-molecule inhibitor of Ref-1 for non-proliferative diabetic retinopathy.
Lead Product(s): APX3330
Therapeutic Area: Ophthalmology Brand Name: APX3330
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Ocuphire Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 22, 2024
Lead Product(s) : APX3330
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Ocuphire Pharma
Deal Size : Undisclosed
Deal Type : Merger
Ocuphire Pharma Announces Acquisition of Opus Genetics
Details : The acquisition creates a leading, clinical-stage company focused on developing gene therapies, including APX3330, an oral small-molecule inhibitor of Ref-1 for non-proliferative diabetic retinopathy.
Brand Name : APX3330
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 22, 2024
Details:
OPGx-LCA5 is an AAV8 vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis resulting from biallelic mutations in the LCA5 gene.
Lead Product(s): OPGx-LCA5
Therapeutic Area: Rare Diseases and Disorders Brand Name: OPGx-LCA5
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2024
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Opus Genetics Receives FDA Rare Pediatric Disease Designation for OPGx-LCA5
Details : OPGx-LCA5 is an AAV8 vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis resulting from biallelic mutations in the LCA5 gene.
Brand Name : OPGx-LCA5
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 20, 2024
Details:
The proceeds will be used to conduct a preclinical safety study for OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations (RHO-adRP).
Lead Product(s): OPGx-RHO
Therapeutic Area: Genetic Disease Brand Name: OPGx-RHO
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Foundation Fighting Blindness
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding June 13, 2024
Lead Product(s) : OPGx-RHO
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Foundation Fighting Blindness
Deal Size : $1.7 million
Deal Type : Funding
Opus Genetics Announces $1.7 Million in Funding for Preclinical Programs
Details : The proceeds will be used to conduct a preclinical safety study for OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations (RHO-adRP).
Brand Name : OPGx-RHO
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 13, 2024
Details:
OPGx-LCA5 uses an AAV8 vector to deliver a functional LCA5 gene to the retina for patients with Leber congenital amaurosis from LCA5 mutations.
Lead Product(s): OPGx-LCA5
Therapeutic Area: Rare Diseases and Disorders Brand Name: OPGx-LCA5
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Opus Genetics Completes Dosing in Phase 1/2 Trial of Gene Therapy OPGx-LCA5
Details : OPGx-LCA5 uses an AAV8 vector to deliver a functional LCA5 gene to the retina for patients with Leber congenital amaurosis from LCA5 mutations.
Brand Name : OPGx-LCA5
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 26, 2024
Details:
OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).
Lead Product(s): OPGx-LCA5
Therapeutic Area: Rare Diseases and Disorders Brand Name: OPGx-LCA5
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).
Brand Name : OPGx-LCA5
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 07, 2023
Details:
Opus Genetics' AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies.
Lead Product(s): AAv-based Gene Therapy
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Recipient: IVERIC bio
Deal Size: Undisclosed Upfront Cash: $0.5 million
Deal Type: Acquisition December 28, 2022
Lead Product(s) : AAv-based Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : IVERIC bio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Opus Genetics' AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $0.5 million
December 28, 2022
Details:
OPGx-001 is an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5gene to retinal photoreceptors. Preclinical studies in in vitro and in vivo models of LCA5 have provided support for the safety and efficacy of OPGx-001.
Lead Product(s): AAV8.hLCA5
Therapeutic Area: Rare Diseases and Disorders Brand Name: OPGx-001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Lead Product(s) : AAV8.hLCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OPGx-001 is an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5gene to retinal photoreceptors. Preclinical studies in in vitro and in vivo models of LCA5 have provided support for the safety and efficacy of OPGx-001.
Brand Name : OPGx-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 01, 2022
Details:
Preclinical data, including faithful animal and human iPSC models, have demonstrated preservation of visual function when OPGx-001 was administered prior to peak disease severity, indicating the potential for a broad therapeutic window for patients with LCA5.
Lead Product(s): OPGx-001
Therapeutic Area: Genetic Disease Brand Name: OPGx-001
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Lead Product(s) : OPGx-001
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical data, including faithful animal and human iPSC models, have demonstrated preservation of visual function when OPGx-001 was administered prior to peak disease severity, indicating the potential for a broad therapeutic window for patients with ...
Brand Name : OPGx-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 04, 2022
Details:
Data support continued development of OPGx-001, designed to address mutations in LCA5 gene and OPGx-002, restoring protein expression caused by mutations in RDH12 gene, to address mutations in genes causing forms of Leber congenital amaurosis.
Lead Product(s): OPGx-002
Therapeutic Area: Genetic Disease Brand Name: OPGx-002
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Lead Product(s) : OPGx-002
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data support continued development of OPGx-001, designed to address mutations in LCA5 gene and OPGx-002, restoring protein expression caused by mutations in RDH12 gene, to address mutations in genes causing forms of Leber congenital amaurosis.
Brand Name : OPGx-002
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 28, 2022
Details:
Resilience will provide process and analytical development, quality control testing, and GMP manufacturing services for IND-enabling toxicology and first-in-human material for Opus’ adeno-associated viral (AAV) vector-based gene therapies including OPGx-001, OPGx-002 and OPGx-003.
Lead Product(s): OPGx-001
Therapeutic Area: Genetic Disease Brand Name: OPGx-001
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: National Resilience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 11, 2022
Lead Product(s) : OPGx-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : National Resilience
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Resilience will provide process and analytical development, quality control testing, and GMP manufacturing services for IND-enabling toxicology and first-in-human material for Opus’ adeno-associated viral (AAV) vector-based gene therapies including OPG...
Brand Name : OPGx-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 11, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?